Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13-Reference-Cited by-同舟云学术

Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13

Published:2020-08-31 Issue:1 Volume:21 Page:37-46
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Parigi Tommaso Lorenzo¹,D’Amico Ferdinando²,Peyrin-Biroulet Laurent³,Danese Silvio⁴⁵^ORCID

Affiliation:

1. Department of Biomedical Sciences, Humanitas University, Milan, Italy

2. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

3. Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France

4. Department of Gastroenterology, Humanitas Clinical and Research Center - IRCCS, IBD Center, Milan, Italy

5. Department of Biomedical Sciences, Pieve Emanuele, Humanitas University, Milan, Italy

Funder

funded

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2020.1811849

Reference67 articles.

1. Ulcerative colitis

2. Crohn's disease

3. Danese S, Fiorino G, Peyrin-Biroulet L. Positioning therapies in ulcerative colitis. W.B. Saunders; 2020. p. 1280–1290.e1. Clin. Gastroenterol. Hepatol. * This study reports the most recent evidence for the therapeutic management of patients with ulcerative colitis.

4. Table 1, cost comparison table of biologics for the treatment of Crohn’s Disease - Entyvio (Vedolizumab) - NCBI Bookshelf [Internet]. [cited 2020 May 30]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK424364/table/T68/.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of selected serum biomarkers levels in response to the infliximab reference product (Remicade®) versus its biosimilar (Remsima®) in a sample of ulcerative colitis patients: a cross-sectional study;F1000Research;2023-12-06

2. Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease;Expert Review of Clinical Immunology;2023-08-13

3. Oxidative Stress, Inflammation, Gut Dysbiosis: What Can Polyphenols Do in Inflammatory Bowel Disease?;Antioxidants;2023-04-20

4. Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience;Journal of Clinical Medicine;2022-12-08

5. Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics;Journal of Clinical Medicine;2022-10-19